NasdaqGM:IRONBiotechs
Will FDA Bitopertin Rejection and New Legal Probe Change Disc Medicine's (IRON) Narrative?
Rosen Law Firm recently began investigating potential securities claims on behalf of Disc Medicine shareholders, following the FDA’s February 2026 Complete Response Letter rejecting approval of the company’s bitopertin program and requesting additional evidence.
This combination of regulatory setback and legal scrutiny raises fresh questions about Disc Medicine’s prior communications around bitopertin’s prospects and supporting data.
We’ll now examine how the FDA’s Complete Response Letter...